Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data

  • Gabriel, Rafael
  • Abdelkader, Nisa Boukichou
  • Acosta, Tania
  • Gilis-Januszewska, Aleksandra
  • Gómez-Huelgas, Ricardo
  • Makrilakis, Konstantinos
  • Kamenov, Zdravko
  • Paulweber, Bernhard
  • Satman, Ilhan
  • Djordjevic, Predrag
  • AlkandariI, Abdullah
  • Mitrakou, Asimina
  • Lalic, Nebojsa
  • Colagiuri, Stephen
  • Lindström, Jaana
  • Egido de los Ríos, Jesús
  • Natali, Andrea
  • Pastor, J. Carlos
  • Teuschl, Yvonne
  • Lind, Marcus
  • Silva, Luis
  • López-Ridaura, Ruy
  • Tuomilehto, Jaakko
  • On behalf of the e-PREDICE Consortium
Objectives To assess the effects of early management of hyperglycaemia with antidiabetic drugs plus lifestyle intervention compared with lifestyle alone, on microvascular function in adults with pre-diabetes. Methods Trial design: International, multicenter, randomised, partially double-blind, placebo-controlled, clinical trial. Participants Males and females aged 45–74 years with IFG, IGT or IFG+IGT, recruited from primary care centres in Australia, Austria, Bulgaria, Greece, Kuwait, Poland, Serbia, Spain and Turkey Intervention Participants were randomized to placebo; metformin 1.700 mg/day; linagliptin 5 mg/day or fixed-dose combination of linagliptin/metformin. All patients were enrolled in a lifestyle intervention program (diet and physical activity). Drug intervention will last 2 years. Primary Outcome: composite end-point of diabetic retinopathy estimated by the Early Treatment Diabetic Retinopathy Study Score, urinary albumin to creatinine ratio, and skin conductance in feet estimated by the sudomotor index. Secondary outcomes in a subsample include insulin sensitivity, beta-cell function, biomarkers of inflammation and fatty liver disease, quality of life, cognitive function, depressive symptoms and endothelial function Results One thousand three hundred ninety one individuals with hyperglycaemia were assessed for eligibility, 424 excluded after screening, 967 allocated to placebo, metformin, linagliptin or to fixed-dose combination of metformin + linagliptin. A total of 809 people (91.1%) accepted and initiated the assigned treatment. Study sample after randomization was well balanced among the four groups. No statistical differences for the main risk factors analysed were observed between those accepting or rejecting treatment initiation. At baseline prevalence of diabetic retinopathy was 4.2%, severe neuropathy 5.3% and nephropathy 5.7%. Conclusions ePREDICE is the first -randomized clinical trial with the aim to assess effects of different interventions (lifestyle and pharmacological) on microvascular function in people with prediabetes. The trial will provide novel data on lifestyle modification combined with glucose lowering drugs for the prevention of early microvascular complications and diabetes, All the funding or sources of support received during this specific study: - European Commission, FP7 EC-GA No. 279074 - Merck- Serono, Germany - Boeringher Ingelheim, Germany (IIS Program. Grant number 1218.166) - Instituto de Salud Carlos III, Spain PI11/01653
Repisalud
Publicación Artículo científico (JournalArticle)

Prevalence and factors linked to renal involvement in prediabetes patients across Europe in the ePREDICE trial

  • Más-Fontao, Sebastián
  • Civantos, Esther
  • Boukichou-Abdelkader, Nisa
  • Moreno, Juan A
  • Tuomilehto, Jaakko
  • Gabriel-Sanchez, Rafael
  • Egido, Jesús
This sub-analysis of the ePREDICE trial, investigated the prevalence and determinants of renal complications, specifically glomerular hyperfiltration, albuminuria, and reduced kidney function, in individuals with prediabetes (PD). The cohort consisted of 967 participants from diverse backgrounds across seven countries. The kidney function was evaluated using the MDRD-4 equation, and the influence of various clinical and demographic factors on renal involvement was assessed by multivariable regression models. Additionally, insulinogenic and disposition indices were examined. Overall, the prevalence of renal abnormalities in this PD cohort was 9.2% (n = 89). Key findings included the detection of hyperfiltration in 20 (2%) individuals, albuminuria in 45 (4.7%), and CKD stage G3a in 29 (3%). Hyperfiltration was inversely correlated with age and height, while albuminuria showed a significant direct association with the disposition index (DI). Age and waist circumference were significantly and directly associated with estimated glomerular filtration rate (eGFR). The ePREDICE study highlights critical factors that affect renal involvement in PD individuals, revealing complex interactions among various parameters. These findings further emphasize the necessity for the search of early kidney abnormalities in people with PD especially in those in older age groups and with a large waist circumference.
Repisalud
Publicación Artículo científico (JournalArticle)

Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial

  • Gabriel-Sanchez, Rafael
  • Boukichou-Abdelkader, Nisa
  • Gilis-Januszewska, Aleksandra
  • Makrilakis, Konstantinos
  • Gómez-Huelgas, Ricardo
  • Kamenov, Zdravko
  • Paulweber, Bernhard
  • Satman, Ilhan
  • Djordjevic, Predrag
  • Alkandari, Abdullah
  • Mitrakou, Asimina
  • Lalic, Nebojsa
  • Egido, Jesús
  • Más-Fontao, Sebastián
  • Calvet, Jean Henri
  • Pastor, José Carlos
  • Lindström, Jaana
  • Lind, Marcus
  • Acosta, Tania
  • Silva, Luis
  • Tuomilehto, Jaakko
  • E-Predice Consortium
Objective: To compare the effect of glucose-lowering drugs on peripheral nerve and kidney function in prediabetes. Methods: Multicenter, randomized, placebo-controlled trial in 658 adults with prediabetes treated for 1 year with metformin, linagliptin, their combination or placebo. Endpoints are small fiber peripheral neuropathy (SFPN) risk estimated by foot electrochemical skin conductance (FESC < 70 μSiemens) and estimated glomerular filtration rate (eGFR). Results: Compared to the placebo, the proportion of SFPN was reduced by 25.1% (95% CI:16.3-33.9) with metformin alone, by 17.3% (95% CI 7.4-27.2) with linagliptin alone, and by 19.5% (95% CI 10.1-29.0) with the combination linagliptin/metformin (p < 0.0001 for all comparisons). eGFR remained +3.3 mL/min (95% CI: 0.38-6.22) higher with the combination linagliptin/metformin than with the placebo (p = 0.03). Fasting plasma glucose (FPG) decreased more with metformin monotherapy -0.3 mmol/L (95%CI: -0.48; 0.12, p = 0.0009) and with the combination metformin/linagliptin -0.2 mmol/L (95% CI: -0.37; -0.03) than with the placebo (p = 0.0219). Body weight (BW) decreased by -2.0 kg (95% CI: -5.65; -1.65, p = 0.0006) with metformin monotherapy, and by -1.9 kg (95% CI: -3.02; -0.97) with the combination metformin/linagliptin as compared to the placebo (p = 0.0002). Conclusions: in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo.